<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00226187</url>
  </required_header>
  <id_info>
    <org_study_id>1</org_study_id>
    <nct_id>NCT00226187</nct_id>
  </id_info>
  <brief_title>A Randomized Clinical Trial on Supplementation of DHA and AA to Preterm Infants</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Oslo</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Oslo</source>
  <brief_summary>
    <textblock>
      A randomized, double-blind trial of docosahexaenoic and arachidonic acid supplementation in&#xD;
      breast-fed preterm infants&#xD;
&#xD;
      Background:&#xD;
&#xD;
      Docosahexaenoic acid (DHA) and arachidonic acid (AA) are essential for preterm infants. Human&#xD;
      milk and preterm formulas contain DHA and AA, but at lower concentrations than required to&#xD;
      approximate utero accretion rate.&#xD;
&#xD;
      Objective:&#xD;
&#xD;
      To evaluate the effect of a high dose DHA and AA supplement to breast-fed preterm infants in&#xD;
      the early neonatal period. Primary endpoints are neurodevelopment at 6 and 20 months of age.&#xD;
&#xD;
      Design:&#xD;
&#xD;
      A randomized double-blind placebo-controlled study is carried out in four Norwegian neonatal&#xD;
      centers.&#xD;
&#xD;
      Subjects and methods:&#xD;
&#xD;
      Infants with birth weight &lt; 1.5 kg are randomized to either an intervention or a control&#xD;
      group. All infants receive fortified human milk, and a daily dose of 0.5 ml study oil per 100&#xD;
      ml milk. Infants in the intervention group receive oil with DHA and AA (Formulaid, Martek,&#xD;
      USA), while the control oil contains vegetable oil without DHA or AA. Blood samples are&#xD;
      collected at birth (cord), and at start and stop of the intervention. Plasma is analyzed for&#xD;
      fatty acid pattern using high performance liquid chromatography.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2003</start_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cognitive development</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Growth</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
  </secondary_outcome>
  <enrollment>140</enrollment>
  <condition>Infant, Low Birth Weight</condition>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Supplement of fatty acid (DHA and AA)</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Birth weight &lt; 1500 g&#xD;
&#xD;
          -  Born at one of 4 participating neonatal centers in Norway&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Cerebral haemorrhage (stage 3 or 4)&#xD;
&#xD;
          -  Major congenital malformations that are supposed to affect growth and development&#xD;
&#xD;
          -  Illness that require prolonged parenteral nutrition (&gt;4 weeks)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>1 Month</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christian A Drevon, Dr. Med.</last_name>
    <role>Study Chair</role>
    <affiliation>University og Oslo</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Oslo</name>
      <address>
        <city>Oslo</city>
        <zip>0316</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Norway</country>
  </location_countries>
  <verification_date>September 2005</verification_date>
  <study_first_submitted>September 22, 2005</study_first_submitted>
  <study_first_submitted_qc>September 23, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 26, 2005</study_first_posted>
  <last_update_submitted>February 14, 2007</last_update_submitted>
  <last_update_submitted_qc>February 14, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 15, 2007</last_update_posted>
  <keyword>Fatty acids</keyword>
  <keyword>Human milk</keyword>
  <keyword>Infant development</keyword>
  <keyword>Very low birthweight infants</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Birth Weight</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

